Court Favors Boehringer In Third Pradaxa Bellwether Trial
Court Favors Boehringer In Third Pradaxa Bellwether Trial
Introduction
A Hartford Superior Court ruled in favor of Boehringer Ingelheim Pharmaceuticals in the third bellwether trial involving claims by a man who suffered bleeding due to the alleged use of blood thinner medication Pradaxa.
The trial for claims brought by the plaintiff in 2016 concluded after a three-week deliberation, and it is the third straight win for Boehringer. The first two trials held in March 2018 and May 2018 also ended in a defense verdict. The next bellwether trial involving claims of health hazards of Pradaxa will begin in February 2019.
Pradaxa was initially approved by the U.S. FDA to be used as a blood thinner, but reports suggest it causes serious injuries and gastrointestinal bleeding, heart attack, stroke, brain hemorrhage, kidney bleeding, and death. Judge Herndon, who overlooked Pradaxa class action lawsuits, recommended a shutdown of the multidistrict litigation (MDL No. 2385) in December 2017 after dismissing pending cases in the docket.
Latest News
title demo for news
Zantac Settles 4,000 Lawsuits in U.S. Courts
Sanofi has announced a settlement agreement regarding approximately 4,000 Zantac cancer lawsuits filed in state courts across the country.
…Valsartan Recall Lawsuit Set for Trial
Years after the initiation of Valsartan recalls, the U.S. District Judge overseeing lawsuits filed by individuals harmed by tainted versions of…